Virtual Library
Start Your Search
R. Hagmann
Author of
-
+
P1.07 - Poster Session with Presenters Present (ID 459)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.07-041 - Validation of Prognostic Scores in Small Cell Lung Cancer (ID 6205)
14:30 - 14:30 | Author(s): R. Hagmann
- Abstract
Background:
Treatment decisions in small-cell lung cancer (SCLC) are made based on the extent of the disease. However, the outcome differs among patients at the same stage. A simple tool to predict outcome in SCLC patients would be helpful for decision-making. In recent years, several prognostic scores have been proposed. However, most of them have never been validated in independent patient population.
Methods:
From January 2000 to December 2010, 92 SCLC patients were treated at our institution. Data acquisition from consecutive patients was done through patients’ medical records, and blood results recorded at the time of diagnosis. Univariate and multiple cox regression analyses of survival were performed to assess the prognostic value of relevant clinical and laboratory factors for SCLC. Furthermore, we investigated the relationship between seven published prognostic scores for SCLC and overall survival (OS).
Results:
We recently published clinical data of our study population (Hagmann R. J Cancer 2015). In a univariate analysis, we evaluated 29 parameters. Staging (p<0.001), number of metastastic sites (p<0.001), liver metastasis (p<0.001), bone metastasis (p<0.001), adrenal gland metastasis (p=0.028) and response to initial therapy (p<0.001) were significantly related to OS. From the established laboratory markers hypoalbuminemia (<35 g/l; p=0.044), hyponatraemia (<131 mmol/l; p=0.041), and elevated alkaline phosphatase (AP) (≥ 129 U/l; p<0.001) significantly predicted OS. Multivariate analysis confirmed staging (HR 2.7; p=0.022) and elevated AP (HR 3.3; p=0.004) as independent prognostic factors. The Manchester Score incorporating LDH, tumor stage, serum sodium, Karnofsky performance status, AP and serum bicarbonate (Cerny T. Int J Cancer 1987) was the only published scoring system significantly associated with OS. Patients in good, intermediate and poor prognosis groups had a median OS of 12.9, 6.6 and 5.8 months, respectively (p=0.008).
Conclusion:
We confirmed the prognostic role of the Manchester Score in an independent patient population whereas the reliability of more complex and recent scoring systems could not be validated. We therefore recommend using simple clinical and laboratory factors instead of complex scores to estimate prognosis of SCLC patients.
